SPC
GNMK

Sigma Planning Corp’s GenMark Diagnostics, Inc GNMK Stock Holding History

Sigma Planning Corp’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-11,457
Closed -$163K – 1273
2020
Q3 		$163K Buy
+11,457
New +$175K 0.01% 984

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sigma Planning Corp's GNMK Position: Q4 2020 in Review

Sigma Planning Corp sold out of GenMark Diagnostics, Inc (GNMK) in Q4 2020, closing a stake of 11,457 shares — an estimated $163K sold.

Sigma Planning Corp first reported a position in GNMK in Q3 2020 and held it in 1 quarter. The position peaked at $163K in Q3 2020. 151 funds tracked by Wall St. Rank hold GNMK as of Q4 2020.

  • Sigma Planning Corp reported no remaining GenMark Diagnostics, Inc position as of Q4 2020 after selling out during the quarter.
  • Sigma Planning Corp sold 11,457 GenMark Diagnostics, Inc shares in Q4 2020, an estimated $163K.
  • Sigma Planning Corp first reported a position in GenMark Diagnostics, Inc in Q3 2020 and held it in 1 quarter.
  • Sigma Planning Corp's GenMark Diagnostics, Inc position peaked at $163K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q4 2020.

Based on Sigma Planning Corp's 13F filing for Q4 2020, filed 9 Feb 2021.